INM - InMed Quick Ratio

InMed Pharmaceuticals (INM) operates in the biopharma sector, where demand remains stable, although raw material logistics and patent law are subject to geopolitical influence. This chart, where the indicator stands at 1.39, confirms the asset's price action. InMed Pharmaceuticals generates revenue by developing dermatology and ophthalmology treatments via cannabinoid biosynthesis. The business currently relies on B2B technologies for the therapy of rare pathologies while awaiting FDA approval.

Analyzing solvency is critical for identifying fundamental leaders in biopharmaceuticals. This ratio measures the ability to settle short-term debts using cash and accounts receivable, completely excluding illiquid inventory. For InMed Pharmaceuticals (INM), this determines survival amidst costly FDA clinical trials and scientific competition. The trend in the quick ratio allows for the timely detection of cash gap risks.